EMA CHMP Affirms Negative Opinion on Celgene's (CELG) Istodax
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/18/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Adobe has received a takeover approach by a Big Tech company - Betaville
- Medifast launches Trilivy, replacing its Optavia brand
Celgene (CELG) Unit to Request Re-Examination of Negative Opinion on ISTODAX from EMA CHMP
July 20, 2012 10:13 AM EDTCelgene International SÃ rl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced it will request a re-examination of the negative opinion announced by the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) regarding the Marketing... More
